Anthera Pharma: Set to open at record low after lead drug fails study

Anthera Pharmaceuticals

12/03/2018 13:00

** Drug developer's shares  ANTH.O  plunge 85.60 pct to 38
cents in premarket trade; set to open at record low 
    ** Top pct loser among all U.S.-listed stocks 
    ** Says it would evaluate all strategic options after its
lead drug failed in a late-stage trial  urn:newsml:reuters.com:*:nL3N1QU3Y3
    ** Says would stop developing the drug, Sollpura, which
aimed to treat improper digestion due to cystic fibrosis (CF)
    ** In 2016, Sollpura failed another late-stage study to
treat patients with improper digestion due to CF  urn:newsml:reuters.com:*:nL4N1EM3JU
    ** CF is a genetic disease that causes persistent lung
infections and limits ability to breathe over time
    ** Up to Friday's close, ANTH stock had risen 60 pct this
year; fell ~54 pct in the past 12 months

 (Reporting by Akankshita Mukhopadhyay in Bengaluru)
 ((Akankshita.Mukhopadhyay@thomsonreuters.com))